Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies

  • 109 Accesses

  • 4 Citations

Abstract

Aim

The aim of this article was to assess whether the use of closed system drug transfer devices (CSTDs) can successfully extend the shelf-life of intravenous (IV) cytotoxic drugs and thus contribute to financial savings to the pharmacy budget.

Methodology

In two study centres, two 6-month studies of the same design were conducted simultaneously. Three months of withdrawal of IV cytotoxic drugs from vials using conventional needle/syringe methods was compared with 3 months of using a CSTD (Tevadaptor®). During the study, the maximal withdrawable drug quantity from vials and loss due to discarding residuals, mostly in connection with sterility concerns, were measured according to the applied techniques. As the applied CSTD system eliminates microbiological risks, drug shelf-life was extended with CSTD use in the second period. The costs of drugs using conventional dispensing versus CSTD use were also compared.

Results

The amount of drug remaining in vials did not significantly differ between needle/syringe and CSTD use. Amount of drugs saved by CSTD use (through the extension of their shelf-life) was significant in all comparisons. For a set of 9 and 20 generic IV chemotherapy drugs, annual drug cost savings of €54,117 (Centre 1) and €16,901 (Centre 2) may be achieved, representing 3.9 and 3.4 % of the pharmacy budgets of the respective centres. When expensive IV biological drugs are considered, budget savings of up to 18.6 % may be achieved with CSTD use.

Conclusion

Microbiological stability is the largest obstacle in efficient IV drug utilization. It usually means a 24-h expiry after preparation, although the physicochemical stability of the drug exceeds this period. The use of a CSTD, combined with a standard aseptic environment, provides sterility for the admixture during the preparation process. Taking advantage of the extended drug shelf-lives of drugs provided by the use of a CSTD (Tevadaptor® in this study), a significant amount of drug can be saved, resulting in financial benefits for the pharmacy budget.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Kantarjian H, Steensma D, Rius Sanjuan J, et al. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014;10(4):e208–11.

  2. 2.

    Danzon MP, Taylor E. Drug pricing and the value in oncology. Oncologist. 2010;15(1):24–31.

  3. 3.

    Danzon PM, Furukawa MF. Prices and availability of biopharmaceuticals: an international comparison. Health Aff (Millwood). 2006;25(5):1353–62.

  4. 4.

    Simoens S, Dooms M. How much is the life of a cancer patient worth? A pharmaco-economic perspective. J Clin Pharm Ther. 2011;36(3):249–56.

  5. 5.

    Pichon-Riviere A, Garay OU, Augustovski F, et al. Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven Latin American countries. Int J Technol Assess Health Care. 2015;31(1–2):2–11.

  6. 6.

    Wilkinson AS, Caspersen VV, Allwood MC, et al. Data to consider when extending practical (in-use) shelf-life of drug vials with the Tevadaptor® closed system drug transfer device. Teva Medical Ltd; 2014.

  7. 7.

    Vandenbroucke J, Robays H. Economic impact of the preparation scenario for cytotoxic drugs: an observational study. EJHP Pract. 2006;14(5):37–42.

  8. 8.

    Walker SE, Iazzetta J, De Angelis C, et al. Chemotherapy waste reduction through shelf-life extension. Can J Hosp Pharm. 1994;47(1):15–23.

  9. 9.

    Edwards MS, Solimando DA Jr, Grollman FR, et al. Cost savings realized by use of the PhaSeal® closed-system transfer device for preparation of antineoplastic agents. J Oncol Pharm Pract. 2013;19(4):338–47.

  10. 10.

    De Prijck K, D’Haese E, Vandenbroucke J, et al. Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Lett Appl Microbiol. 2008;47(6):543–8.

  11. 11.

    Carey TE, Forrey RA, Haughs D, et al. second look at utilization of a closed-system transfer device (PhaSeal). Am J Pharm Benefits. 2011;3(6):311–8.

  12. 12.

    Northcott M, Allsopp MA, Powell H, et al. The stability of carboplatin, diamorphine, 5-fluorouracil and mitozantrone infusions in an ambulatory pump under storage and prolonged ‘in-use’ conditions. J Clin Pharm Ther. 1991;16(2):123–9.

  13. 13.

    Zhang Y, Trissel LA. Physical and chemical stability of pemetrexed in infusion solutions. Ann Pharmacother. 2006;40(6):1082–5.

  14. 14.

    Zhang Y, Kawedia JD, Myers AL, et al. Physical and chemical stability of high-dose ifosfamide and mesna for prolonged 14-day continuous infusion. J Oncol Pharm Pract. 2014;20(1):51–7.

  15. 15.

    Donyai P, Sewell GJ. Physical and chemical stability of paclitaxel infusions in different container types. J Oncol Pharm Pract. 2006;12(4):211–22.

  16. 16.

    Bing CM. Extended stability for parenteral drugs. 5th ed. American Society of Health-System Pharmacists; 2009.

  17. 17.

    Comprehensive summary of stability studies, sorted according to particular substances. http://www.stabilis.org. Accessed 6 April 2014.

Download references

Author information

Correspondence to Ákos Juhász.

Ethics declarations

Funding

No funding was received by the authors to conduct this study.

Conflicts of interest

Á. Juhász, G. Batka and A. Szücs declare that they have no conflicts of interest relevant to the content of this manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Juhász, Á., Batka, G. & Szűcs, A. Responding to drug shortages and rising costs: IV chemotherapy drug use optimization achieved by closed safety devices in hospital pharmacies. Drugs Ther Perspect 32, 170–176 (2016). https://doi.org/10.1007/s40267-016-0285-6

Download citation

Keywords

  • Bevacizumab
  • Trastuzumab
  • Pemetrexed
  • Hospital Pharmacist
  • Drug Supply